Exacerbations needing hospitalisation · adults with asthma
ICS + LAMA add‐on showed no clear difference in exacerbations requiring hospitalisation 14 weeks compared with ICS dose increase (low certainty).
1 finding from 1 review
Exacerbations leading to ED visits · adults with asthma
ICS + LAMA add‐on showed no clear difference in exacerbations requiring ED visit 14 weeks compared with ICS dose increase (low certainty).
1 finding from 1 review
FEV1 · adults with asthma
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Moderate
ACQ score Scale = 0 to 6 (0 = no impairment; 6 = maximum impairment) · adults with asthma
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Low
Exacerbations (OCS) · adults with asthma not well controlled on ICS
Long‐acting muscarinic antagonists (LAMA) add‐on showed no clear difference in exacerbations (OCS) compared with long‐acting beta2‐agonists (LABA) add‐on (low certainty).
1 finding from 1 review
AQLQ total 1 = severely impaired; 7 = not impaired at all 22 weeks · adults with asthma not well controlled on ICS
1 finding from 1 review
Serious adverse events 22 weeks · adults with asthma not well controlled on ICS
Long‐acting muscarinic antagonists (LAMA) add‐on showed no clear difference in serious adverse events 22 weeks compared with long‐acting beta2‐agonists (LABA) add‐on (low certainty).
1 finding from 1 review
Hospital admission (exacerbation) · adults with asthma not well controlled on ICS
It is very uncertain whether long‐acting muscarinic antagonists (LAMA) add‐on changes exacerbations (hospital) compared with long‐acting beta2‐agonists (LABA) add‐on (very low certainty).
1 finding from 1 review
FEV1 · adults with asthma not well controlled on ICS
1 finding from 1 review
ACQ score Scale = 0 to 6 (0 = no impairment; 6 = maximum impairment) · adults with asthma not well controlled on ICS
1 finding from 1 review
Adverse events (all) · adults with asthma not well controlled on ICS
Long‐acting muscarinic antagonists (LAMA) add‐on showed no clear difference in adverse events (all) compared with long‐acting beta2‐agonists (LABA) add‐on (moderate certainty).
1 finding from 1 review
Sexual satisfaction · Men with COPD
1 finding from 1 review
Effect on later sexual function · Men with COPD
1 finding from 1 review
Adverse events (all cause) · Men with COPD
Testosterone therapy showed no clear difference in adverse events (all cause) compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Exercise capacity (5‐ or 6‐minute walking distance on cylinder air) · adults with COPD who had exertional dyspnoea but did not fulfil the criteria for long‐term oxygen treatment
1 finding from 1 review
Intervention not reported
Mortality · adults with COPD who had exertional dyspnoea but did not fulfil the criteria for long‐term oxygen treatment
The intervention showed no clear difference in mortality (moderate certainty).
1 finding from 1 review
Intervention not reported
Quality of life (dyspnoea) Measured on the CRQ, the output is a number from 0 to 7, where higher on the scale is better. MID is 0.5. · adults with COPD who had exertional dyspnoea but did not fulfil the criteria for long‐term oxygen treatment
The intervention probably leads to higher quality of life (dyspnoea) Measured on the CRQ, the output is a… (moderate certainty).
1 finding from 1 review
Intervention not reported
Dyspnoea · adults with COPD who had exertional dyspnoea but did not fulfil the criteria for long‐term oxygen treatment
1 finding from 1 review
Intervention not reported
Adverse events · adults with COPD who had exertional dyspnoea but did not fulfil the criteria for long‐term oxygen treatment
The intervention showed no clear difference in adverse events (low certainty).
1 finding from 1 review
Intervention not reported
Hospitalisations · adults with COPD who had exertional dyspnoea but did not fulfil the criteria for long‐term oxygen treatment
1 finding from 1 review